Eton Pharmaceuticals Inc

Eton Pharmaceuticals stock surged 41.9% through 2:15 p.m. ET Friday after the rare-disease drug developer reported second-quarter results that beat analyst forecasts and raised its full-year guidance. The company posted a profit of $0.43 per share on $37.6 million in sales, compared with Wall Street expectations of $0.15 per share on $26.9 million in revenue. Sales nearly doubled year over year, and Eton flipped from a $0.10 per share GAAP loss to a $0.35 per share profit. The company also licensed the rights to infantile hemangioma drug candidate ASN-001 from Auson Pharmaceuticals, and raised its revenue guidance to exceed $145 million for the year, well above the $121 million analysts had expected.

Eton Pharmaceuticals shares rallied 25% in premarket trading on Friday after the company reported record quarterly revenue and issued 2026 guidance exceeding $145 million with an adjusted EBITDA margin target above 35%. CEO Sean Brynjelsen highlighted significant margin expansion and progress across the commercial portfolio and pipeline, along with several strategic transactions to support long-term growth. The company reiterated a net realized price of $8,000 to $10,000 for HEMANGEOL and said commercial focus is shifting to volume growth and converting patients from off-label adult product use. Eton Pharmaceuticals stock is up over 140% year to date.

Five biotech stocks highlighted in RTTNews reports have delivered gains ranging from 100% to over 300% since their respective publication dates. Climb Bio Inc. rose 310% to $12.90 from a published price of $3.14 on December 15, 2025, driven by pipeline progress and positive early clinical data for Budoprutug and CLYM116. Tectonic Therapeutic Inc. gained 121% to $37.93 from $17.15 on October 27, 2025, following positive Phase 1b results for TX45 and initiation of multiple clinical trials. UroGen Pharma Ltd. climbed 280% to $38.02 from $10.01 on April 25, 2025, after FDA approval of Zusduri and strong revenue growth. Eton Pharmaceuticals Inc. advanced 128% to $37.50 from $16.44 on December 11, 2025, supported by FDA approval of DESMODA and multiple commercial deals. Liquidia Corp. surged 249% to $78.93 from $22.59 on October 17, 2025, fueled by the launch and expanding adoption of Yutrepia.